ROBERTO HEGG

(Fonte: Lattes)
Índice h a partir de 2011
15
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Tipo de acesso: restrictedAccess ×

Resultados de Busca

Agora exibindo 1 - 10 de 35
  • article 61 Citação(ões) na Scopus
    Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer ROSiA Single-Arm Phase 3B Study
    (2017) OZA, Amit M.; SELLE, Frederic; DAVIDENKO, Irina; KORACH, Jacob; MENDIOLA, Cesar; PAUTIER, Patricia; CHMIELOWSKA, Ewa; BAMIAS, Aristotelis; DECENSI, Andrea; ZVIRBULE, Zanete; GONZALEZ-MARTIN, Antonio; HEGG, Roberto; JOLY, Florence; ZAMAGNI, Claudio; GADDUCCI, Angiolo; MARTIN, Nicolas; ROBB, Stephen; COLOMBO, Nicoletta
    Objective: The aim of this study was to assess the safety and efficacy of extending bevacizumab therapy beyond 15 months in nonprogressive ovarian cancer. Patients and Methods: In this multinational prospective single-armstudy (ClinicalTrials.gov NCT01239732), eligible patients had International Federation of Gynecology and Obstetrics stage IIB to IVor grade 3 stage I to IIA ovarian cancer without clinical signs or symptoms of gastrointestinal obstruction or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the preceding 6 months. Prior neoadjuvant chemotherapy was permitted. After debulking surgery, patients received bevacizumab 15 (or 7.5) mg/kg every 3 weeks (q3w) with 4 to 8 cycles of paclitaxel (investigator's choice of 175 mg/m(2) q3w or 80 mg/m(2) weekly) plus carboplatin AUC 5 to 6 q3w. Single-agent bevacizumab was continued until progression or for up to 24 months. The primary end point was safety. Results: Between December 2010 and May 2012, 1021 patients from 35 countries began study treatment. Bevacizumab was administered at 15 mg/kg in 89% of patients and for more than 15 months in 53%. Median follow-up duration was 32 months (range, 1-50 months). The most common all-grade adverse events were hypertension (55% of patients), neutropenia (49%), and alopecia (43%). The most common grade 3 or higher-grade adverse events were neutropenia (27%) and hypertension (25%). Bevacizumab was discontinued because of proteinuria in 5% of patients and hypertension in 3%. Median progression-free survival (PFS) was 25.5 months (95% confidence interval, 23.7-27.6 months). Conclusion: Extended bevacizumab demonstrated increased incidences of proteinuria and hypertension compared with 12 or 15 months of bevacizumab in previous trials, but these rarely led to bevacizumab discontinuation. Median PFS is the longest reported for front line bevacizumab-containing therapy. The longer bevacizumab duration beyond 15 months in this study may improve PFS without substantially compromising safety.
  • conferenceObject
    IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemotherapy in early triple-negative breast cancer (TNBC)
    (2020) HARBECK, N.; ZHANG, H.; BARRIOS, C. H.; SAJI, S.; JUNG, K. H.; HEGG, R.; KOEHLER, A.; SOHN, J.; IWATA, H.; TELLI, M. L.; FERRARIO, C.; PUNIE, K.; PENAULT-LLORCA, F.; PATEL, S.; DUC, A. Nguyen; LISTE-HERMOSO, M.; MAIYA, V.; MOLINERO, L.; CHUI, S. Y.; MITTENDORF, E.
  • conferenceObject
    Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study
    (2020) HAMILTON, Erika P.; CORTES, Javier; JERUSALEM, Guy; KAUFMAN, Peter A.; OZYILKAN, Ozgur; HEGG, Roberto; LITCHFIELD, Lacey M.; WANG, Hong; GRAHAM, Hillary T.; WIJAYAWARDANA, Sameera R.; JANSEN, Valerie M.; MARTIN, Miguel
  • article 292 Citação(ões) na Scopus
    Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
    (2012) ISMAEL, Gustavo; HEGG, Roberto; MUEHLBAUER, Susanne; HEINZMANN, Dominik; LUM, Bert; KIM, Sung-Bae; PIENKOWSKI, Tadeusz; LICHINITSER, Mikhail; SEMIGLAZOV, Vladimir; MELICHAR, Bohuslav; JACKISCH, Christian
    Background A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with the standard intravenous infusion of the drug. We compared the pharmacokinetic profile, efficacy, and safety of the subcutaneous and intravenous formulations in patients with HER2-positive early breast cancer. Methods The HannaH study was a phase 3, randomised, international, open-label, trial in the (neo)adjuvant setting. Patients with HER2-positive, operable, locally advanced or inflammatory breast cancer were randomly assigned to eight cycles of neoadjuvant chemotherapy administered concurrently with trastuzumab every 3 weeks either intravenously (8 mg/kg loading dose, 6 mg/kg maintenance dose) or subcutaneously (fixed dose of 600 mg); 1: 1 ratio. Chemotherapy consisted of four cycles of docetaxel (75 mg/m(2)) followed by four cycles of fluorouracil (500 mg/m(2)), epirubicin (75 mg/m(2)), and cyclophosphamide (500 mg/m(2)), every 3 weeks. After surgery, patients continued trastuzumab to complete 1 year of treatment. Coprimary endpoints were serum trough concentration (C-trough) at pre-dose cycle 8 before surgery (non-inferiority margin for the ratio between groups of 0.80) and pathological complete response (pCR; non-inferiority margin for the difference between groups of -12.5%), analysed in the per-protocol population. This study is registered with ClinicalTrials.gov, number NCT00950300. Findings 299 patients were randomly assigned to receive intravenous trastuzumab and 297 to receive subcutaneous trastuzumab. The geometric mean presurgery C-trough was 51.8 mu g/mL (coefficient of variation 52.5%) in the intravenous group and 69.0 mu g/mL (55.8%) in the subcutaneous group. The geometric mean ratio of C-trough subcutaneous to C-trough intravenous was 1.33 (90% CI 1.24-1.44). 107 (40.7%) of 263 patients in the intravenous group and 118 (45.4%) of 260 in the subcutaneous group achieved a pCR. The difference between groups in pCR was 4.7% (95% CI -4.0 to 13.4). Thus subcutaneous trastuzumab was non-inferior to intravenous trastuzumab for both coprimary endpoints. The incidence of grade 3-5 adverse events was similar between groups. The most common of these adverse events were neutropenia (99 [33.2%] of 298 patients in the intravenous group vs 86 [29.0%] of 297 in the subcutaneous group), leucopenia (17 [5.7%] vs 12 [4.0%]), and febrile neutropenia (10 [3.4%] vs 17 [5.7%]). However, more patients had serious adverse events in the subcutaneous group (62 [21%] of 297 patients) than in the intravenous group (37 [12%] of 298); the difference was mainly attributable to infections and infestations (24 [8.1%] in the subcutaneous group vs 13 [4.4%] in the intravenous group). Four adverse events led to death (one in the intravenous group and three in the subcutaneous group), all of which occurred during the neoadjuvant phase. Of these, two-both in the subcutaneous group-were deemed to be treatment related. Interpretation Subcutaneous trastuzumab, administered over about 5 min, has a pharmacokinetic profile and efficacy non-inferior to standard intravenous administration, with a similar safety profile to intravenous trastuzumab, and therefore offers a valid treatment alternative.
  • article 2065 Citação(ões) na Scopus
    Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    (2012) BASELGA, Jose; CORTES, Javier; KIM, Sung-Bae; IM, Seock-Ah; HEGG, Roberto; IM, Young-Hyuck; ROMAN, Laslo; PEDRINI, Jose Luiz; PIENKOWSKI, Tadeusz; KNOTT, Adam; CLARK, Emma; BENYUNES, Mark C.; ROSS, Graham; SWAIN, Sandra M.
    BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.)
  • conferenceObject
    Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T plus AI vs L plus AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.
    (2017) GRADISHAR, William John; HEGG, Roberto; IM, Seock-Ah; PARK, In Hae; TJULANDIN, Sergei; KENNY, Sarah; SARP, Severine; WILLIAMS, Lisa; IZQUIERDO, Miguel A.; JOHNSTON, Stephen R. D.
  • article 149 Citação(ões) na Scopus
    First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
    (2018) RIMAWI, Mothaffar; FERRERO, Jean-Marc; HABA-RODRIGUEZ, Juan de la; POOLE, Christopher; PLACIDO, Sabino De; OSBORNE, C. Kent; HEGG, Roberto; EASTON, Valerie; WOHLFARTH, Christine; ARPINO, Grazia
    PurposeTo assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).Patients and MethodsThe PERTAIN trial (NCT01491737) is an ongoing randomized, open-label, multicenter80 sites and eight countriesphase II trial. Patients have HER2-positive, hormone receptor-positive MBC/LABC and no prior systemic therapy with the exception of endocrine. Random assignment was 1:1 to intravenous pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks) plus trastuzumab (8 mg/kg followed by 6 mg/kg every 3 weeks), and oral anastrozole (1 mg every day) or letrozole (2.5 mg every day), or trastuzumab and an AI. Induction intravenous docetaxel every 3 weeks or paclitaxel every week could be administered for 18 to 24 weeks at the investigator's discretion (decided before but given after random assignment). Primary end point was progression-free survival (PFS). Patients were stratified by whether they received induction chemotherapy and their time since adjuvant hormone therapy.ResultsOne hundred twenty-nine patients were randomly assigned per arm (February 2012 to October 2014; intent-to-treat populations); 75 in one arm and 71 in the other were chosen to receive induction chemotherapy. Stratified median PFS was 18.89 months (95% CI, 14.09 to 27.66 months) in the pertuzumab plus trastuzumab arm and 15.80 months (95% CI, 11.04 to 18.56 months) in the trastuzumab arm (stratified hazard ratio, 0.65; 95% CI, 0.48 to 0.89; P = .0070). Serious adverse events (AEs) were reported for 42 (33.1%) of 127 and 24 (19.4%) of 124 patients in the safety populations of the pertuzumab plus trastuzumab and trastuzumab arms, respectively. Rates of grade 3 AEs were 64 (50.4%) of 127 and 48 (38.7%) of 124, respectively. There were no deaths as a result of AEs.ConclusionPERTAIN met its primary PFS end point. Pertuzumab plus trastuzumab and an AI is effective for the treatment of HER2-positive MBC/LABC. The safety profile was consistent with previous trials of pertuzumab plus trastuzumab.
  • conferenceObject
    Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).
    (2021) MARTIN, Miguel; HEGG, Roberto; KIM, Sung-Bae; SCHENKER, Michael; GRECEA, Daniela; GARCIA-SAENZ, Jose A.; PAPAZISIS, Konstantinos; OUYANG, Quchang; LACKO, Aleksandra; OKSUZOGLU, Berna; REEVES, James Andrew; OKERA, Meena; TESTA, Laura; SHIMIZU, Chikako; WEI, Ran; FORRESTER, Tammy D.; MUNOZ, Maria; ZIMMERMANN, Annamaria H.; HEADLEY, Desiree; JOHNSTON, Stephen R. D.
  • conferenceObject
    nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer
    (2021) HUOBER, J.; HAMILTON, E.; CORTES, J.; OZYILKAN, O.; CHEN, S. C.; PETRAKOVA, K.; MANIKHAS, A.; JERUSALEM, G.; HEGG, R.; CHAPMAN, S.; YANG, Z.; CHEN, Y.; JOHNSTON, E.; MARTIN, M.
  • article 75 Citação(ões) na Scopus
    Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
    (2019) BACHELOT, T.; CIRUELOS, E.; SCHNEEWEISS, A.; PUGLISI, F.; PERETZ-YABLONSKI, T.; BONDARENKO, I.; PALUCH-SHIMON, S.; WARDLEY, A.; MEROT, J. -L.; TOIT, Y. du; EASTON, V.; LINDEGGER, N.; MILES, D.; BOUZID, Kamel; CAMPONE, Mario; COUDERT, Bruno; NOWECKI, Zbigniew; ERRIHANI, Hassan; DALENC, Florence; FERREIRA, Ana; MANO, Max; RICCI, Francesco; KALOFONOS, Haralabos; ANDREETTA, Claudia; MONTEMURRO, Filippo; BARRETT, Sophie; ZHANG, Qingyuan; MAVROUDIS, Dimitris; MATUS, Juan; BEATO, Carlos; HU, Xichun; GAAFAR, Rabab; AZEEM, Hamdy Abdel; PERRIN, Christophe; ETTL, Johannes; LANG, Istvan; VERMA, Sunil; LI, Huiping; BRAIN, Etienne; HOFFMANN, Oliver; CARIELLO, Anna; TONDINI, Carlo; ALTWEGEIRI, Taher; LOMAN, Niklas; LUX, Michael; FRASSOLDATI, Antonio; AZIZ, Zeba; SALAS, Fernando; STREB, Joanna; WRONSKI, Andrzej; BELTRAN, Salomon Menjon; CICIN, Irfan; SCHMID, Peter; LAING, Robert; TONG, Zhongsheng; BOER, Katalin; JUHASZ, Balazs; GIANNI, Luca; CURIGLIANO, Giuseppe; JUAREZ, Alejandro; MATOS, Erika; USLU, Ruchan; WILDIERS, Hans; CRUZ, Marcelo; BOURGEOIS, Hugues; SCHUMANN, Raquel von; STEMMER, Salomon; VASQUEZ, Flavia Morales; DOMINGUEZ, Adriana; WOJTUKIEWICZ, Marek; TRIFUNOVIC, Jasna; ILLARRAMENDI, Jose Juan; GARCIA, Laura; PERON, Yann Izarzugaza; ECHARRI, Maria Jose; VOITKO, Natliia; WHEATLEY, Duncan; WATERS, Simon; BOER, Richard De; JERUSALEM, Guy; COCQUYT, Veronique; BARRIOS, Carlos; PANASCI, Lawrence; MATTSON, Johanna; TANNER, Minna; GOZY, Michel; VASILOPOULOS, Georgios; REVESZ, Janos; LATINI, Luciano; GRIDELLI, Cesare; LAZARO, Jesus; GONZALEZ, Antonio; MOLINS, Agusti Barnadas; MARTINEZ, Eduardo; ALARCON, Jesus; ARANCE, Ana; KLINT, Leif; KOVALYOV, Oleksiy; BAIRD, Richard; YEO, Belinda; MCCARTHY, Nicole; GREIL, Richard; WANG, Shusen; ARTIGNAN, Xavier; AUGEREAU, Paule; JUHASZ-BOESS, Ingolf; NGAN, Roger; GOLDBERG, Hadassah; COSTANZO, Francesco Di; FERRAU, Francesco; ALEKNAVICIUS, Eduardas; RASHID, Kamran; COSTA, Luis; GARCIA, Jose Angel; CRUZ, Luis Ruiz de la; LOPEZ, Rafael Lopez; VAL, Olga Del; OZYILKAN, Ozgur; AZRIBI, Fathi; VERRILL, Mark; TURNER, Nicholas; BEITH, Jane; PETZER, Andreas; ANDRADE, Jurandyr; BERNSTEIN, Vanessa; RAYSON, Daniel; ELDIN, Ibtessam Saad; ACHILLE, Mihaela; MUELLER, Volkmar; GENNARI, Alessandra; CASCINU, Stefano; GHOSN, Marwan; EL-SAGHIR, Nagi; BOSCH, Joan Van den; OOSTERKAMP, Rianne; KUKULSKA, Monika; PELAEZ, Ignacio; HERNANDEZ, Carolina; GORDON, Maria del Mar; DALMAU, Elsa; ALONSO, Jose Luis; AKSOY, Sercan; COSKUN, Hasan Senol; SHPARYK, Yaroslav; VARUGHESE, Mohini; PANWAR, Udaiveer; BARRACLOUGH, Lisa; LEVITT, Nicola; HICKS, Jonathan; RIGG, Anna; ALLEN, Mark; CASTILLO, Cecila; FEIN, Luis Enrique; STUART-HARRIS, Robin; SINGER, Christian; STOEGER, Herbert; SMILJANIC, Sasha; FENG, Jifeng; CEDENO, Miguel; BERDAH, Jean Francois; ORFEUVRE, Hubert; GONCALVES, Anthony; GRISCHKE, Eva-Maria; SIMON, Eike; WAGNER, Steffen; EFREMIDOU, Anna; PAPAZISIS, Konstantinos; EVRON, Ella; INBAR, Moshe; BARUCH, Noa Ben; GEFFEN, David; KARMINSKY, Natalya; RUGGERI, Enzo Maria; LUIGI, Cavanna; GRASSO, Donatella; JUOZAITYTE, Elona; CID, Jeronimo Rafael Rodriguez; ROERDINK, Henk; SIDDIQI, Neelum; COELHO, Jose Luis Passos; GARRE, Elisa Garcia; GARCIA, Andres; JANEZ, Noelia Martinez; CEBALLOS, Maria Helena Lopez; MELE, Mireia; GARCIA, Maria; ARCEDIANO, Alberto; MCADAM, Karen; PERREN, Timothy; HICKS, Jonathan; TAYLOR, Wendy; HUMPHREYS, Alison; VERA, Raul; STEGER, Guenther; ANDEL, Johannes; GREVE, Jacques de; HUIZING, Manon; HEGG, Roberto; JOY, Anil; SEHDEV, Sandeep; KUTNER, Riina; RUOHOLA, Johanna; DOHOLLOU, Nadine; GROSJEAN, Jessica; LAPLAIGE, Philippe; LARGILLIER, Remy; MARTIN, Philippe; POTTIER, Virginie; ALEXANDRE, Jerome; CHRISTENSEN, Bernd; ZAHM, Dirk-Michael; KHANDAN, Fariba; LUECK, Hans-Joachim; FOUNTZILAS, Georgios; FRIED, Georgeta; GIACOBINO, Alice; BONETTI, Andrea; GUERRA, Yanin Chavarri; WARMERDAM, Laurens Van; VELDEN, Annette Van der; VRIJALDENHOVEN, Suzan; JONGH, Felix de; CAVERO, Milagros; CONEJERO, Raquel Andres; MURIAS, Adolfo; SAURA, Salvador; OLTRA, Amparo; REDONDO, Andres; RIBELLES, Nuria; BACHMEIER, Kilian; JOFFE, Johnathan; CHAKRABORTI, Prabir; BERESFORD, Mark; BUTT, Mohammad; POOLE, Christopher; YORDI, Gassan; WOODWARD, Natasha; AMORIM, Gilberto; CALIFARETTI, Nadia; FOX, Susan; ROBIDOUX, Andre; LI, NanLi; LI, Nenxiao; JIANG, Jun; SORIA, Tannia; PADRIK, Peeter; SAARNI, Outi; GENET, Dominique; CATALA, Stephanie; BARLETTA, Hugues; TEIXEIRA, Luis; FACCHINI, Thomas; HESSE, Tobias; KUEHN, Thorsten; OBER, Angelika; REPP, Roland; SCHROEDER, Willibald; PECTASIDES, Dimitrios; BODOKY, Gyorgy; KAHAN, Zsuzsanna; JIVELIOUK, Irina; ROSENGARTEN, Ora; ALABISO, Oscar; PEREZ, Mario; WOUW, Yes Van de; SMOK-KALWAT, Jolanta; DAMASCENO, Margarida; SOUSA, Gabriela; ABULKHAIR, Omalkhair; TORRES, Antonio Anton; MARTINEZ, Maria Purificacion; MATA, Jesus Garcia; JERICO, Marta Santisteban Jesus Florian; LLOMBART, Antonio; SANCHEZ, Rosa; TORREGO, Juan Carlos; GARATE, Clara Olier; RODRIGUEZ, Cesar; LLORENTE, Rosa; PRADO, Diego Soto de; CORTES, Javier; LLORCA, Cristina; GALAN, Antonio; VILLARO, Gemma Vinas; NARBE, Ulrik; BJOMEKLETT, Helena Granstam; WESTWELL, Sarah; NEWBY, Jackie; JAFRI, Mariam; RODRIGUEZ, Robinson; ALONSO, Isabel
    Background: Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the phase III CLEOPATRA trial. PERUSE was designed to assess the safety and efficacy of investigator-selected taxane with pertuzumab and trastuzumab in this setting. Patients and methods: In the ongoing multicentre single-arm phase IIIb PERUSE study, patients with inoperable HER2-positive advanced breast cancer (locally recurrent/metastatic) (LR/MBC) and no prior systemic therapy for LR/MBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab [8 mg/kg loading dose, then 6 mg/kg every 3 weeks (q3w)] and pertuzumab (840 mg loading dose, then 420 mg q3w) until disease progression or unacceptable toxicity. The primary end point was safety. Secondary end points included overall response rate (ORR) and progression-free survival (PFS). Results: Overall, 1436 patients received at least one treatment dose (initially docetaxel in 775 patients, paclitaxel in 589, nab-paclitaxel in 65; 7 discontinued before starting taxane). Median age was 54 years; 29% had received prior trastuzumab. Median treatment duration was 16 months for pertuzumab and trastuzumab and 4 months for taxane. Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (all-grade peripheral neuropathy 31% versus 16%) but less febrile neutropenia (1% versus 11%) and mucositis (14% versus 25%). At this preliminary analysis (52 months' median follow-up), median PFS was 20.6 [95% confidence interval (CI) 18.9-22.7] months overall (19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). ORR was 80% (95% CI 78%-82%) overall (docetaxel 79%, paclitaxel 83%, nab-paclitaxel 77%). Conclusions: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile.